 |
SHANGHAI, April 7, 2025 /PRNewswire/ -- DualityBio announced today that Dr. Hua Mu has joined the company as Global Chief Medical Officer (CMO). In this role, Dr. Mu will oversee the strategic planning, meticulous design, efficient execution, and comprehensive regulatory compliance of the company's global clinical development efforts, ensuring adherence to the most stringent international regulatory standards.
Dr. Mu holds an M.D. degree from West China University of Medical Sciences and a Ph.D. degree from the University of California, Berkeley. With decades of global experience in drug research, translational medicine, and clinical development, he has held leadership roles at top multinational pharmaceutical companies, biotech firms, and top-tier capital, successfully advancing multiple drug candidates from preclinical stages through commercialization. As a seasoned biotech executive and drug developer, Dr. Mu's extensive expertise and global vision will provide strategic leadership in driving clinical development programs and navigating regulatory landscapes.
"Dr. Mu's appointment comes at a pivotal moment as DualityBio approaches a new milestone in the capital markets," said Dr. John Zhu, Founder and CEO of DualityBio. "His unique blend of full-cycle development experience in multinational pharma and hands-on expertise in the globalization of China's innovative drugs will strengthen our global multicenter clinical trial strategy. By implementing scientifically rigorous clinical development plans, we will enhance pipeline value and build clinical development infrastructure and capability fully aligned with FDA, EMA, and NMPA requirements. We are confident that Dr. Mu will accelerate our clinical progress, fuel DualityBio's global expansion, and solidify our leadership in next-generation ADC innovation."
Dr. Mu stated: "I am honored to embark on this new journey with DualityBio. My decision to join stems from a deep alignment with the company's global vision. My mission is to build a team with international regulatory expertise, integrate clinical resources across the U.S., Europe, and China, and accelerate NDA filings for core assets—all while driving DualityBio's global clinical-commercial flywheel. Together, we will transition from a biotech to a biopharma, delivering accessible breakthrough therapies to patients worldwide."
SHANGHAI, April 7, 2025 /PRNewswire/ -- DualityBio announced today that Dr. Hua Mu has joined the company as Global Chief Medical Officer (CMO). In this role, Dr. Mu will oversee the strategic planning, meticulous design, efficient execution, and comprehensive regulatory compliance of the company's global clinical development efforts, ensuring adherence to the most stringent international regulatory standards.
Dr. Mu holds an M.D. degree from West China University of Medical Sciences and a Ph.D. degree from the University of California, Berkeley. With decades of global experience in drug research, translational medicine, and clinical development, he has held leadership roles at top multinational pharmaceutical companies, biotech firms, and top-tier capital, successfully advancing multiple drug candidates from preclinical stages through commercialization. As a seasoned biotech executive and drug developer, Dr. Mu's extensive expertise and global vision will provide strategic leadership in driving clinical development programs and navigating regulatory landscapes.
"Dr. Mu's appointment comes at a pivotal moment as DualityBio approaches a new milestone in the capital markets," said Dr. John Zhu, Founder and CEO of DualityBio. "His unique blend of full-cycle development experience in multinational pharma and hands-on expertise in the globalization of China's innovative drugs will strengthen our global multicenter clinical trial strategy. By implementing scientifically rigorous clinical development plans, we will enhance pipeline value and build clinical development infrastructure and capability fully aligned with FDA, EMA, and NMPA requirements. We are confident that Dr. Mu will accelerate our clinical progress, fuel DualityBio's global expansion, and solidify our leadership in next-generation ADC innovation."
Dr. Mu stated: "I am honored to embark on this new journey with DualityBio. My decision to join stems from a deep alignment with the company's global vision. My mission is to build a team with international regulatory expertise, integrate clinical resources across the U.S., Europe, and China, and accelerate NDA filings for core assets—all while driving DualityBio's global clinical-commercial flywheel. Together, we will transition from a biotech to a biopharma, delivering accessible breakthrough therapies to patients worldwide."
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Duality Bio Appoints Hua Mu as Global Chief Medical Officer
SYDNEY, Jan. 13, 2026 /PRNewswire/ -- DoxAI, the rapidly growing AI automation and document-intelligence company within the Lakeba Group, today announced the appointment of Roberto Purcaro as a Non-Executive Director.
Strengthening Strategic Oversight for International Growth
Roberto brings more than 20 years of international investment banking experience, most recently as Global Head of Complex Opportunities and Head of Italy at Macquarie Capital. He has structured major high profile transactions worldwide in infrastructure, energy transition and digitalisation working with multinational corporations, sovereign institutions, and leading global investors allowing Macquarie to expand the business to new geographies and products.
His appointment significantly enhances the Board's strategic expertise, particularly as DoxAI accelerates its international expansion. Roberto's proven track record and extensive global network will provide invaluable strategic guidance to management.
Leadership Commentary
Giuseppe Porcelli, Chairman of DoxAI and Group CEO of Lakeba, said:
"Roberto's appointment marks a major milestone in DoxAI's global expansion. His experience leading complex, high-value transactions with strategic relationships will accelerate our growth into key international markets. Roberto strengthens our board at a pivotal moment as we scale DoxAI into one of the world's most advanced AI automation platforms."Kevin Wo, Independent Non-Executive Director of DoxAI and Chief Partner Officer, Microsoft ASEAN, added:
"Roberto brings world-class strategic and financial insight to our Board. His addition enhances the Board's ability to guide DoxAI's global journey, and I look forward to working closely with him as we deepen our international presence and expand our portfolio of enterprise-grade AI solutions."
Roberto Purcaro, incoming Non-Executive Director of DoxAI, said:
"I am thrilled to join DoxAI at such an exciting stage. The company has developed an impressive foundation of technology, customers and global partnerships, and I see enormous potential to scale its impact globally. I look forward to working with my fellow directors and the management team to provide strategic guidance on international growth opportunities that will help realise DoxAI's significant global potential."
About Roberto Purcaro
Roberto Purcaro is a highly regarded international investment banker with a track record of leading transformative transactions in infrastructure, technology and energy transition.Former Global Head of Complex Opportunities and Head of Italy at Macquarie Ccapital, he is recognised for structuring innovative deals and scaling businesses across borders.
About DoxAI
DoxAI is a leading AI automation and document-intelligence platform created by Lakeba Group. DoxAI provides enterprise-grade solutions for classification, extraction, validation, fraud detection, summarisation, e-signing and document workflow automation. The platform powers operations across financial services, telecommunications, professional services, government and supply-chain industries — enabling organisations to reduce cost, increase efficiency and modernise compliance through AI-driven decisioning.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
DoxAI Appoints Former Macquarie Capital Executive Roberto Purcaro to its Board of Directors to Accelerate Global Expansion
